Hysterectomy

Insights on Global Medical Robotics Systems Market Size & Share Projected to Hit at USD 38834 Million and Rise at a CAGR of 16.80% By 2028: Industry Trends, Demand, Value, Analysis & Forecast Report | Zion Market Research

Retrieved on: 
Monday, August 8, 2022
Laparoscopy, Pharmacy, Bleeding, Growth, Obstetrics, Hospital, Medical tourism, American College, Patient, Gynaecology, Hysterectomy, Disease, Rancho Los Amigos National Rehabilitation Center, MIS, Solution, Neurosurgery, Efficiency, Adoption, 3D printing, Computer data storage, Medical device

Minimally invasive robotic surgery contributes to these benefits by ensuring higher accuracy and reproducibility, as well as better control and efficiency.

Key Points: 
  • Minimally invasive robotic surgery contributes to these benefits by ensuring higher accuracy and reproducibility, as well as better control and efficiency.
  • On the other hand, procedures using robotic platforms usually show conversion rates of less than 5%, reducing morbidity and blood loss.
  • Global Medical Robotics Systems Market: Opportunities
    Emerging markets and growing medical tourism to bring up growth prospects for the market.
  • Global Medical Robotics Systems Market: Segmentation
    The global medical robotics systems market is segregated on the basis of product & service, application, end-user, end user, and region.

Minerva Surgical Announces Time To Talk Campaign

Retrieved on: 
Wednesday, August 3, 2022
Minerva, Internet, OH, Abnormal uterine bleeding, Hysterectomy, Woman, OBGYN, Market, Obstetrics, GLOBE, Social media, Uterus, AUB, Company, Time, Internal bleeding, Medical device

The Uterine Health Company (Nasdaq: UTRS), focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced their Time To Talk social media campaign and local event series.

Key Points: 
  • The Uterine Health Company (Nasdaq: UTRS), focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced their Time To Talk social media campaign and local event series.
  • AUB encompasses a variety of causes and symptoms that can leave women feeling as if life revolves around their period.
  • The Clinical Education team at Minerva recently began hosting Time To TalkLIVE in person events.
  • Attending a Time To TalkLIVE event is a fantastic first step in initiating the discussion, said Mike Clapper, Director of Brand Strategy at Market Development at Minerva Surgical.

HEALTHGRADES RECOGNIZES 145 LEADING HOSPITALS FOR EXCELLENCE ACROSS OBSTETRICS & GYNECOLOGY

Retrieved on: 
Tuesday, August 2, 2022
Gynaecology, View, Obstetrics and gynaecology, Hospital, Solution, Purchase Tax, Risk, Multimedia, EVP, Labour, Vaginal delivery, MD, Patient, Spying on United Nations leaders by United States diplomats, Hope, Medicine, Health insurance, Obstetrics, Healthgrades, Hysterectomy

DENVER, Aug. 2, 2022 /PRNewswire/ -- Healthgrades , the #1 website Americans use to find a doctor or hospital, today announced the National Leaders in Obstetrics & Gynecology: the recipients of the 2022 Healthgrades Labor and Delivery Excellence Award, the Gynecologic Surgery Excellence Award, and the Overall Obstetrics and Gynecology Award.

Key Points: 
  • DENVER, Aug. 2, 2022 /PRNewswire/ -- Healthgrades , the #1 website Americans use to find a doctor or hospital, today announced the National Leaders in Obstetrics & Gynecology: the recipients of the 2022 Healthgrades Labor and Delivery Excellence Award, the Gynecologic Surgery Excellence Award, and the Overall Obstetrics and Gynecology Award.
  • The 2022 awards identify the top 10% of hospitals in each area of Obstetrics & Gynecology.
  • 145 hospitals were recognized across the three awards, including 17 extremely high-performing facilities that achieved all three awards.
  • A few notable statistics about the top performing hospitals include:
    From 2018-2020, if all hospitals in the 16 states included in this analysis, as a group, performed similarly to hospitals receiving the Obstetrics and Gynecology Excellence Award, on average, 153,369 patients could have avoided complications.

Penn Highlands Healthcare Physician Performs Innovative Procedure for Pelvic Organ Prolapse

Retrieved on: 
Friday, July 29, 2022
Neurosurgery, Hysterectomy, GLOBE, Physician, Tissue, Food, Hospital, Woman, POP, Family, Collection, Pharmacy, Travel, Pelvic organ prolapse, Pelvic floor, Uterus, Cancer, Park Street, Food and Drug Administration, Nursing, MD, Patient, Pain, Vagina, Muscle, Suite, Gynaecology, Rectum, Birth control

Betty Milburn traveled 32 miles from her home in Derry, Pennsylvania to Penn Highlands Connellsville in Fayette County Pennsylvania to have Michael Pelekanos, MD, perform the EnPlace procedure to correct her pelvic organ prolapse.

Key Points: 
  • Betty Milburn traveled 32 miles from her home in Derry, Pennsylvania to Penn Highlands Connellsville in Fayette County Pennsylvania to have Michael Pelekanos, MD, perform the EnPlace procedure to correct her pelvic organ prolapse.
  • Mrs. Milburns family practice physician suggested that she see Dr. Pelekanos who performs the mesh-free minimally invasive EnPlace procedure at Penn Highlands Connellsville.
  • Dr. Pelekanos is a urogynecologist with Penn Highlands Healthcare, which is one of only a few health systems in the United States offering the unique, Food and Drug Administration-cleared procedure.
  • Penn Highlands Healthcare was officially formed in 2011, and is comprised of eight hospitals Penn Highlands Brookville, Penn Highlands Clearfield, Penn Highlands Connellsville, Penn Highlands DuBois, Penn Highlands Elk, Penn Highlands Huntingdon, Penn Highlands Mon Valley and Penn Highlands Tyrone -- that have served area communities for the past 100+ years.

Minerva Surgical to Announce Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, July 28, 2022
Nasdaq, AUB, Woman, Uterus, Holocene, Hysterectomy, Telephone, GLOBE, Abnormal uterine bleeding, Company, Minerva, Medical device

SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022.

Key Points: 
  • SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
  • The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

AHN West Penn Hospital Recognized as one of the Nation's Top 50 Best Hospitals for Obstetrics and Gynecology by U.S. News and World Report

Retrieved on: 
Wednesday, July 27, 2022
Drexel University College of Medicine, Neurosurgery, Hysterectomy, Diabetes, Jefferson Health, Lake Erie College, Physician, Organ transplantation, AHN, Network, Hospital, Woman, Saint Vincent Hospital, AGH, Radiation, Mother, Research, Allegheny Health Network, Cardiovascular disease, Kidney failure, James Forbes (hospital inspector), Health, Obstetrics, News, Esophageal cancer, Pregnancy, Cell, National Association Medical Staff Services, Women's Institutes, Lake Erie College of Osteopathic Medicine, Mental health, Patient, Stroke, Survival, Heart failure, COPD, Neurology, Ovarian cancer, Gynecologic Oncology (journal), Gynaecology, Autoimmune disease, U.S. News & World Report, Chair, Osteopathic medicine in the United States, Health insurance, Medicine, Pharmaceutical industry, Melanoma, U.S, MD, Cancer, Western Pennsylvania Hospital

PITTSBURGH, July 27, 2022 /PRNewswire-PRWeb/ -- Multiple other AHN Hospitals Achieve High Performing Status Across Numerous Specialties

Key Points: 
  • AHN West Penn Hospital, Allegheny Health Network's flagship hospital for women's health care, has been named one of the top 50 hospitals in the nation for obstetrics and gynecology, according to the U.S. News and World Report Best Hospitals Rankings, released to the public today.
  • AHN West Penn Hospital , Allegheny Health Network 's flagship hospital for women's health care, has been named one of the top 50 hospitals in the nation for obstetrics and gynecology , according to the U.S. News and World Report Best Hospitals Rankings, released to the public today.
  • West Penn was ranked 31st in the nation for obstetrics and gynecology, making it the highest positioned hospital in the greater western Pennsylvania region for those specialties.
  • "Congratulations to all the professionals at West Penn who helped make this exciting recognition from U.S. News possible," said Brian Johnson, MD, President, West Penn Hospital.

Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

Retrieved on: 
Thursday, July 21, 2022
Hysterectomy, Sung, Stanford University, University, GLOBE, Corporate development, Physician, U.S. Securities and Exchange Commission, AUB, San Diego State University, Woman, Forward-looking statement, Guidant, SEC, Executive, Mechanical engineering, Research, Risk, Securities Act of 1933, Securities Exchange Act of 1934, Marketing, Board, Minerva, Abnormal uterine bleeding, COVID-19, Uterus, Review, AllianceBernstein, Director, Technology, Business development, Company, Boston Scientific, Nasdaq, Doctor of Philosophy, Neuromodulation, Projection, LLC, Boston Consulting Group, Management, Medical device, Biological engineering

We are excited to have Derrick Sung, Ph.D. join the Board of Directors of Minerva Surgical, said Ross Jaffe, M.D., Chairman of the Board.

Key Points: 
  • We are excited to have Derrick Sung, Ph.D. join the Board of Directors of Minerva Surgical, said Ross Jaffe, M.D., Chairman of the Board.
  • Derrick brings a wealth of experience in finance, corporate strategy, marketing, and business development that will add a valuable perspective to our Board discussions.
  • I am honored to join the Minerva Surgical Board of Directors, said Dr.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

Retrieved on: 
Monday, July 18, 2022
Other Health, Research, Managed Care, General Health, Pharmaceutical, Consumer, Clinical Trials, Science, Women, Biotechnology, Other Science, Health, Half-life, History, Recurrence, CEO, Woman, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NOT, VVC, Communication, Person, Salpingoophorectomy, Capsule, Inflammation, Vaginal discharge, Food, Technology, Hypersensitivity, Insurance, Infertility, BCRP, Medication, Scott Richter, Incidence, Hysterectomy, Fetus, Commonwealth, Pain, Risk, Urination, Fungus, Enzyme, Candidiasis, Rosuvastatin, CYP51, FDA, Irritation, Toxicity, Education, CYP, Achievement, Pharmaceutical industry, Birth control

Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.

Key Points: 
  • Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.
  • To support effective two-way communication between patients and healthcare providers, we will encourage patients to ask their doctor if VIVJOA is right for them.
  • RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection in 12 months.
  • Mycovia Pharmaceuticals is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies.

New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options

Retrieved on: 
Friday, July 1, 2022
Education, Influencer, Health, Women, Communications, Health Technology, Medical Devices, Digital Marketing, Surgery, Consumer, Other Education, HOLX, Patient, Life, Science, Research, Clothing, Breast cancer, The Harris Poll, Health, Uterine fibroid, COVID-19, Sale, Company, Fibroid, Female, Pain, Awareness, United States Department of Health and Human Services, Woman, Cyst, Uterus, Hysterectomy, Nasdaq, Human services, Cervical cancer, Polyp, Infertility, Solution, Language, Leadership, Physician, News, Mammography, Pharmaceutical industry, Birth control, Health insurance, Online gambling, Hologic

A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

Key Points: 
  • A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.
  • Today, in conjunction with the start of Fibroid Awareness Month, Hologic is proud to announce the launch of Hey, U!, an educational campaign focused on uterine health.
  • "There is a sizeable knowledge gap when it comes to overall uterine health, including symptoms and treatment options for common issues like uterine fibroids."
  • Additional content includes a patient symptom quiz, downloadable discussion guides and information on various fibroid treatment solutions.

The Worldwide Postpartum Hemorrhage Devices Industry is Expected to Reach $1 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Medical Devices, Health, Consumer, Surgery, Women, Baby, Maternity, Smart contract, Bleeding, Lists of countries and territories, Maternal death, Postpartum bleeding, Internal bleeding, Gynaecology, PPH, Death, Childbirth, Oxytocin, Disease, Obstetrics, Mortality, Uterus, World, UBT, Hypovolemia, CAGR, Hysterectomy, World Health Organization, Tranexamic acid, Don't Underestimate My Love for You, American College, Uterine balloon tamponade, Method, WHO, Pet, Birth control

The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.

Key Points: 
  • The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.
  • Postpartum hemorrhage (PPH) is the most prevalent type of obstetric hemorrhage and one of the primary causes of maternal mortality.
  • The postpartum hemorrhage devices market is growing due to a rise in complications such as acute postpartum hemorrhage.
  • Underestimations of blood loss lead healthcare providers into believing that deployment of postpartum hemorrhage are not necessary, thus, limiting the use of postpartum hemorrhage devices.